Clinical trials
Lung Diseases trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Recruiting | 11 |
| Active, not recruiting | 5 |
| Terminated | 3 |
| Enrolling by invitation | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 16 |
| Pfizer | 3 |
| Eli Lilly and Company | 2 |
| Novartis Pharmaceuticals | 2 |
| United Therapeutics | 2 |
| Upstream Bio Inc. | 2 |
| Checkpoint Therapeutics, Inc. | 1 |
| Daiichi Sankyo | 1 |
| Grifols Therapeutics LLC | 1 |
| Hoffmann-La Roche | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases | 44 |
| Respiratory Tract Diseases | 24 |
| Asthma | 14 |
| Lung Diseases, Obstructive | 14 |
| Bronchial Diseases | 13 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Pulmonary Disease, Chronic Obstructive | 10 |
| Lung Neoplasms | 9 |
| Neoplasms | 8 |
| Thoracic Neoplasms | 6 |
Trials
Showing 51 to 44 of 44. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.